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The authors appreciate the comments by Drs. Gatti
and Bertazzoli concerning our case report on fatal
hepatotoxicity secondary to the non-steroidal antiin-
ﬂammatory drug (NSAID) nimesulide. We have taken
up the criticism that our method for calculating the
odds ratio for hepatic adverse eﬀects is not applicable
since nimesulide and COX-2 selective NSAIDs confer
a smaller risk of gastrointestinal side eﬀects, thus
rendering the denominator of our odds ratio calcula-
tion too variable. We have repeated the odds ratio
analysis on unsolicited reports of drug-related side
eﬀects registered in the World Health Organization
database (online search kindly performed by R. Stoller
from the Pharmacovigilance Centre of the ‘‘Interkan-
tonale Kontrollstelle fu¨r Heilmittel’’ IKS, Bern,
Switzerland). To test the hypothesis of Drs. Gatti and
Bertazzoli, we have compared the proportion of
hepatic side eﬀects in relation to (i) the total number
of reported side eﬀects and (ii) the total number of
reported side eﬀects excluding gastrointestinal side
eﬀects. As shown in Table 1, exclusion of adverse
reports related to the gastrointestinal tract does not
change the odds ratio estimate, thereby invalidating
this concern. In contrast to nimesulide, which clearly
shows the highest odds ratio for hepatic adverse eﬀects
of all NSAIDs (Table 1), the odds ratio of the coxib
celecoxib is only 0.8 (95% conﬁdence interval 0.6, 1.0)
in comparison with ibuprofen.
The second comment of Drs. Gatti and Bertazzoli
questions our assumption that the total number of
reports approximately reﬂects the relative prescription
frequencies, since not all NSAIDs exhibit similar
frequencies in causing hepatic and gastrointestinal
ADRs. We entirely agree that calculation of an
absolute risk is undoubtedly the best measure of the
importance of a drug-side eﬀect association, since it
indicates how commonly an ADR is likely to occur in
a group of exposed individuals. However, for the
calculation of absolute risks it is essential that the
primary data sources for the drugs in question are
comparable. In the absence of rigorously controlled
randomised trials or of comprehensive pharmacoepi-
demiological databases, the likelihood of confounding
biases that compromise the validity of the results is no
less than in the observational approach adopted by us.
For nimesulide, the absolute risk is calculated from
the number of spontaneous reports divided by the
sales ﬁgures. However, underreporting is a well-
established serious problem for spontaneous report
systems [1, 2]. Because nimesulide is mainly marketed
in countries with a low frequency of ADR reporting in
relation to population size, the problem of under-
reporting is further aggravated. We would like to
emphasise that the relative risk or odds ratio is the
most frequently reported epidemiological parameter
and is well suited for establishing an association
between a drug and an ADR in the context of an
established causality.
The third concern relates to the increased reporting
rate secondary to the sharpened awareness of and
sensitisation to a particular side eﬀect of a drug. As
shown in Table 2, it is of note that the odds ratio for
nimesulide was already signiﬁcantly elevated (9.6 in
comparison with ibuprofen in 1996/1997) before the
ﬁrst report of nimesulide-induced acute liver injury
was published in 1998. This excludes the possibility of
a reporting bias secondary to publications in the lit-
erature and is a further indication that nimesulide
indeed causes hepatic ADRs more frequently than
other NSAIDs.
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Table 2 Spontaneous reports registered in the World Health Or-
ganization database of hepatic side eﬀects related to nimesulide in
comparison with ibuprofen: inﬂuence of time on odds ratio esti-
mate. Note that the ﬁrst publication on nimesulide-associated acute
liver injury was published in 1998, whereas the reporting odds ratio
for nimesulide-associated hepatic side eﬀects was already clearly
elevated during the preceding years. For further details see legend
of Table 1. CI conﬁdence interval
Years included Reported side eﬀects for Odds ratio (95%CI)
Nimesulide Ibuprofen
Hepatic Others Hepatic Others
All 103 978 385 33,771 9.2 (7.3, 11.6)
2000/2001 39 176 29 2712 20.7 (12, 34)
1998/1999 36 385 54 6568 11.4 (7.3, 17.6)
1996/1997 22 195 40 3462 9.8 (5.6, 16.8)
1994/1995 5 94 38 3129 4.4 (1.6, 11.4)
1992/1993 1 55 28 2647 1.7 (0.2, 12.9)
Table 1 Spontaneous reports registered in the World Health Or-
ganization database of hepatic side eﬀects related to selected non-
steroidal anti-inﬂammatory drugs (NSAIDS). Inﬂuence of the ex-
clusion of gastrointestinal (GI) side eﬀects on odds ratio estimate.
The following categories were considered to represent hepatic side
eﬀects: ‘‘bilirubinaemia’’, ‘‘bilirubinaemia aggravated’’, ‘‘coma he-
patic’’, ‘‘hepatic cirrhosis’’, ‘‘hepatic failure’’, ‘‘hepatic necrosis’’,
‘‘hepatitis’’, ‘‘hepatitis cholestatic’’, ‘‘hepatorenal syndrome’’,
‘‘jaundice’’. The odds ratios of hepatic drug-related side eﬀects in
comparison with ibuprofen were calculated according to Egberts
et al. [3] under the assumption that the total number of reports or
the total number of reports without GI side eﬀects approximately
reﬂects the relative prescription frequencies. Reports registered
prior to 14 November 2001 were included in the analysis. CI con-
ﬁdence interval
Reported side eﬀects Odds ratio (95% CI) in comparison
with ibuprofen based on
Hepatic Others Others excluding
GI
All other reports Other reports
excluding GI
Nimesulide 103 978 762 9.2 (7.3, 11.6) 8.6 (6.8, 10.8)
Sulindac 482 10,183 7957 4.2 (3.6, 4.8) 3.8 (3.3, 4.4)
Diclofenac 1232 35,567 25,800 3.0 (2.7, 3.4) 3.0 (2.7, 3.4)
Ibuprofen 385 33,771 24,460 1.0 1.0
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